| 22.26 Data as of 4:00pm ET |  -0.89 / -3.84%Today’s Change | 15.43 Today|||52-Week Range 26.30 | +34.02% Year-to-Date |
| Alnylam Narrows Loss, Sales Fall - Analyst Blog May 07 / Zacks.com |
| Previous close | 23.15 |
| Today’s open | 23.15 |
| Day’s range | 22.13 - 23.23 |
| Volume | 3,209,407 |
| Average volume (3 months) | 1,289,421 |
| Market cap | $3.1B |
| Dividend yield | -- |
| Earnings growth (last year) | +77.18% |
| Earnings growth (this year) | +70.63% |
| Earnings growth (next 5 years) | +119.62% |
| Revenue growth (last year) | +214.50% |
| P/E ratio | NM |
| Price/Sales | 7.25 |
| Price/Book | -- |
| Today’s change | Today’s % change | |
|---|---|---|
| UTHRUnited Therapeutics ... | +0.36 | +0.53% |
| TAROTaro Pharmaceutical ... | +0.24 | +0.38% |
| JAZZJazz Pharmaceuticals... | +1.51 | +2.58% |
| MDVNMedivation Inc | +1.10 | +2.32% |
| Next reporting date | August 1, 2013 |
| EPS forecast (this quarter) | $0.08 |
| Annual revenue (last year) | $297.1M |
| Annual profit (last year) | -$44.3M |
| Net profit margin | -14.92% |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Paul A. Friedman, MD |
Chief Financial Officer & Executive Vice President David C. Hastings, CPA |
Corporate headquarters Wilmington, Delaware |
.
